Inogen (INGN) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenue increased 5.8% year-over-year to $88.8 million, driven by strong B2B sales growth domestically and internationally, while DTC and rental revenues declined.

• Net loss narrowed significantly to $6.0 million from $45.7 million in Q3 2023, with adjusted net loss at $2.6 million versus $8.5 million prior year.

• Adjusted EBITDA turned positive at $0.5 million, up from a $5.5 million loss in Q3 2023, reflecting disciplined cost management.

• Gross margin improved to 46.5% (up 630 basis points year-over-year), mainly due to lower material costs.

• Cash, equivalents, and marketable securities totaled $124.3 million with no debt outstanding as of September 30, 2024.

Financial highlights

• Q3 2024 revenue: $88.8 million, up 5.8% year-over-year; gross profit: $41.3 million (46.5% margin).

• Domestic B2B revenue grew 35.1% to $23.4 million; international B2B revenue up 26.2% to $32.3 million.

• DTC revenue fell 23.2% to $19.2 million; rental revenue decreased 13.1% to $13.9 million.

• Operating expenses dropped 39% to $49.1 million, reflecting the absence of prior year goodwill impairment.

• Net loss per share: $(0.25) GAAP, $(0.11) adjusted.

Outlook and guidance

• Full-year 2024 revenue guidance raised to $329–$331 million, representing 4–5% year-over-year growth.

• Gross margins expected in the low to mid-40% range for H2 2024; overall adjusted EBITDA loss anticipated.

• DTC channel expected to stabilize and return to growth in 2025, with Patient-First program rollout in H1 2025.